Genmab A (GMAB) Net Income towards Common Stockholders (2018 - 2026)

Genmab A (GMAB) has reported Net Income towards Common Stockholders for 9 consecutive years, with $287.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 64.26% year-over-year to $287.0 million; the trailing twelve-month figure through Jun 2026 stood at $12.5 billion (up 33.75% YoY), and the FY2025 full-year result was $963.0 million, down 28.59% from the prior year.
• Net Income towards Common Stockholders declined to $287.0 million in Q2 2026 per GMAB's latest filing, from $5.7 billion in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $5.8 billion in Q3 2025 and bottomed at -$2.5 billion in Q4 2023.
• Historically, Net Income towards Common Stockholders has averaged $2.0 billion across 5 years, with a median of $2.5 billion in 2022.
• The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders slumped 3568.93% in 2023, then soared 303.27% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at $73.2 million in 2022, then plunged by 3568.93% to -$2.5 billion in 2023, then soared by 220.75% to $3.1 billion in 2024, then soared by 87.66% to $5.8 billion in 2025, then tumbled by 95.01% to $287.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $287.0 million, $5.7 billion, and $5.8 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.